title: Antitumoral activity of a xanthate compound. II. Therapeutic studies in murine leukemia and tumor models in vivo.
abstract: The combinations of tricyclodecan-9-yl-xanthogenate (D 609) with undecanoic acid (C11) and D 609 with myristic acid (C14) were tested in 3 rodent tumor models in vivo. D 609 in combination with C11 or C14 did not show antitumoral efficacy in 3-Lewis lung carcinoma (3-LL) growing in syngeneic C57BL6-mice (primary tumor and metastasis) or in WEHI-3B myelomonocytic leukemia growing in Balb/c mice, when given in a dose range lower than the lethal dose for 10% of the treated animals (LD10). In L 1210 mouse lymphoid leukemia growing in CD2F1 mice the combination of D 609/C11 given intraperitoneally in a concentration of 100 mg/kg for more than 1 day effected a significant difference in the survival curves between the control and therapeutic groups in 1 out of 2 experiments. In conclusion, the treatment schedules of D 609/C11 or D 609/C14 used in this study has not revealed significant therapeutic effects in mouse tumors or leukemias in vivo.
authors.affiliation: Department of Medicine I, Technische Universität, Munich, F.R.G.
authors.forename: H D
authors.initials: HD
authors.lastname: Schick
authors.forename: S
authors.initials: S
authors.lastname: Danhauser-Riedl
authors.forename: E
authors.initials: E
authors.lastname: Amtmann
authors.forename: R
authors.initials: R
authors.lastname: Busch
authors.forename: A
authors.initials: A
authors.lastname: Reichert
authors.forename: G
authors.initials: G
authors.lastname: Steinhauser
authors.forename: J
authors.initials: J
authors.lastname: Rastetter
authors.forename: G
authors.initials: G
authors.lastname: Sauer
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D005227:Fatty Acids / Q000008:administration & dosage; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009227:Myristic Acids / Q000008:administration & dosage; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones / Q000008:administration & dosage
chemical_list: D001952:Bridged-Ring Compounds; D005227:Fatty Acids; D009227:Myristic Acids; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones; C016173:undecanoic acid; C046498:tricyclodecane-9-yl-xanthogenate